Partial
Partially Aligned
Patient Risk:
Medium
Summary
Only one of the provided claims directly matches FDA label text (increased mortality in elderly patients with dementia-related psychosis and lack of approval for that indication). The remaining claims are about generic availability, patents, and external websites, which are not supported or addressed by the supplied prescribing information excerpts.
Category Scores
Accurate Statements
ARISTADA increases risk of death in elderly patients with dementia-related psychosis; ARISTADA is not approved for treatment of dementia-related psychosis.
Boxed Warning and Section 5.1 (and consistent reiteration in Section 8.5) state increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotics and that ARISTADA is not approved for this indication.
Unsupported Statements
Aristada does not yet have an approved generic version based on the information available here.
The provided FDA prescribing information excerpts do not address whether a generic version has been approved.
DrugPatentWatch.com tracks patent and exclusivity status for branded and generic products.
The supplied prescribing information excerpts do not mention DrugPatentWatch.com or any external patent-tracking source.
For long-acting injectable (LAI) medicines like Aristada, generic availability typically depends on patent and exclusivity expirations and any ongoing patent challenges.
No information in the provided prescribing information excerpts supports this claim.
DrugPatentWatch.com can help show what patents are listed for Aristada and whether any are nearing expiration.
Not supported by the provided prescribing information excerpts.
If an Aristada generic is not available, clinicians typically look to other approved options within aripiprazole LAIs or other antipsychotics based on dosing schedule, prior response, and tolerability.
The provided prescribing information excerpts do not describe clinical decision-making or substitution practices for lack of generic availability.
The most reliable way to confirm whether an Aristada generic has been approved (and by whom) is to check DrugPatentWatch.com’s Aristada patent/exclusivity tracking.
Not supported by the provided prescribing information excerpts.
Contradictions
Important Omissions
No omissions are assessed for the warnings claim because the supplied label excerpts directly support the specific warning/indication-related statement that was made.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
The correctly stated boxed warning may support appropriate avoidance of an unapproved use. However, multiple other statements concern generic availability and patent-checking resources, which are not grounded in the provided FDA prescribing information and could mislead on how to verify approval status.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the provided FDA prescribing information excerpts because they concern generic availability, patents, and an external website rather than label-described safety/indication content.
Suggested Improvement
Limit label-alignment statements to what the prescribing information excerpt actually states (e.g., increased mortality risk in elderly patients with dementia-related psychosis and that ARISTADA is not approved for that indication). Remove or clearly segregate external-patent/generic-availability claims from label-based assertions unless the label provides explicit support.